CART-007: a license to kill
Authors:
- 4 September 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (10) , 1145-1146
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesBlood, 2025
- Fratricide-resistant CD7-CAR T cells in T-ALLNature Medicine, 2024
- Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemiaHaematologica, 2024
- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisNew England Journal of Medicine, 2024
- Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2023
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesThe Lancet, 2020
- Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphomaAmerican Journal of Hematology, 2020
- Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunitiesBritish Journal of Haematology, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018